Lilly’s Alimta Gets UK Recommendation As Mesothelioma Therapy
This article was originally published in The Pink Sheet Daily
Oncologic is approved for use in three types of malignant pleural mesothelioma patients by Britain’s National Health Service.
You may also be interested in...
The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.
NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.
Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.